The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Parsabiv
etelcalcetide · ETELCALCETIDE HYDROCHLORIDE 2.5 mg/.5mL · Injection, Solution · Intravenous · Amgen, Inc
NDC 55513-0740-10 · 10 VIAL, SINGLE-DOSE in 1 CARTON / .5 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,083.87
Reported to Texas DSHS · 2026 annual filing · Amgen Usa Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$875,627
6,535 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Amgen Inc.United Stateslabel · pack
- Amgen Manufacturing Limited LLCUnited Statesanalysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA208325
- TE code
- —
- Approval date
- Feb 7, 2017
- Patents / exclusivity
- 24 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11162500 | Jun 27, 2034 |
| patent | 9820938 | Jun 27, 2034 |
| patent | 11162500 | Jun 27, 2034 |
| patent | 9820938 | Jun 27, 2034 |
| patent | 10344765 | Jun 27, 2034 |
| patent | 11162500 | Jun 27, 2034 |
| patent | 11959486 | Jun 27, 2034 |
| patent | 11959486 | Jun 27, 2034 |
| patent | 11959486 | Jun 27, 2034 |
| patent | 10344765 | Jun 27, 2034 |
| patent | 10344765 | Jun 27, 2034 |
| patent | 9820938 | Jun 27, 2034 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of etelcalcetide (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Amgen, Inc | ETELCALCETIDE HYDROCHLORIDE 10 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen, Inc | ETELCALCETIDE HYDROCHLORIDE 2.5 mg/.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen, Inc | ETELCALCETIDE HYDROCHLORIDE 5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Parsabiv — NDC 55513-0740-10," retrieved September 3, 2026, https://drugdashboards.com/drug/55513074010.
Free to cite with attribution — see how the data is put together.